KENT MCDANIEL: Open Payments
NPI 1871640789 · GLEN ALLEN, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$398,591 in 390 payments from 6 companies in 2025. Trend: 2023 $410,179 · 2024 $404,509 · 2025 $398,591
Speaker / faculty: $349,752Travel & lodging: $27,784Consulting: $14,200Food & beverage: $6,855
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 92 | $98,215 |
| Janssen Pharmaceuticals, Inc | 95 | $84,375 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 80 | $79,299 |
| Teva Pharmaceuticals USA, Inc. | 51 | $59,434 |
| Neurocrine BioSciences, Inc. | 47 | $59,044 |
| E.R. Squibb & Sons, L.L.C. | 25 | $18,223 |
Products named: INVEGA SUSTENNA, CAPLYTA, ABILIFY MAINTENA, INGREZZA, UZEDY, AUSTEDO XR, REXULTI, COBENFY.
Industry payments across VA — which companies pay providers there.
